Kymera Therapeutics (KYMR) Non-cash Items (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Non-cash Items data on file, last reported at $410.6 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $410.6 million, up 367.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $410.6 million (up 367.12% YoY), and the FY2025 annual result was $5.9 million, down 4.06% from the prior year.
• Non-cash Items improved to $410.6 million in Q1 2026 per KYMR's latest filing, from $400.5 million in the prior quarter.
• Over five years, Non-cash Items peaked at $410.6 million in Q1 2026 and troughed at $2.8 million in Q2 2022.
• A 5-year average of $110.0 million and a median of $80.7 million in 2024 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2022 and 2024: Non-cash Items surged 2763.88% in 2022, then plunged 92.44% in 2024.
• A 5-year view of Non-cash Items shows it stood at $55.9 million in 2022, then declined by 11.28% to $49.6 million in 2023, then jumped by 96.92% to $97.7 million in 2024, then soared by 309.86% to $400.5 million in 2025, then increased by 2.52% to $410.6 million in 2026.
• Business Quant data shows KYMR's Non-cash Items at $410.6 million in Q1 2026, $400.5 million in Q4 2025, and $31.3 million in Q3 2025.